Agios Pharmaceuticals Q1 Earnings Report and Pipeline Updates
Agios Pharmaceuticals reported Q1 2026 net revenues of $20.7 million for mitapivat, with $18.8 million in U.S. sales. The company expects flat operating expenses in 2026 and highlighted early adoption of AQVESME in thalassemia, though prescription growth is not yet steady. Regulatory progress includes a potential Accelerated Approval filing for mitapivat in sickle cell disease.
Topics: AQVESME Launch Earnings Report Financials Mitapivat Pharmaceuticals Pipeline Catalysts